Record Adjusted EBITDA Margin
Achieved a record adjusted EBITDA margin of 14.2% in Q3, with a 32% year-over-year increase in adjusted EBITDA to $596 million.
Strong Business Development
Net bookings of $8.1 billion, representing a book-to-bill ratio of over 1.9x, and a total backlog of $40.6 billion.
Increased Shareholder Returns
Repurchased $200 million worth of shares and declared a 5.3% increase in the quarterly dividend.
Health and Civil Segment Performance
Health and Civil segment revenue increased 16% with a non-GAAP operating income margin of 24.2%.
Improved Financial Guidance
Raised revenue guidance to $16.35 billion-$16.45 billion for 2024 and increased adjusted EBITDA guidance to the high 12% range.